Synthesis and stability test of radiogadolinium(III)-DOTA-PAMAM G3.0-trastuzumab as SPECT-MRI molecular imaging agent for diagnosis of HER-2 positive breast cancer

Rahmania, Hardiani; Mutalib, Abdul; Ramli, Martalena; Levita, Jutti

doi:10.1016/j.jrras.2014.12.001

Cited by 11 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each fraction was taken (10 L) and tested using the dye protein. In this assay, the fraction containing DOTA-PAMAM G3.0-SH was blue, while the fraction containing no (DOTA)m-PAMAM G3.0-sulfhydril was brown [16]. The positive fractions containing (DOTA)m-PAMAM G3.0-SH were fractions numbered 14-18 ( Fig.…”

Section: Resultsmentioning

confidence: 90%

“…The purification and testing for F(ab') 2 -trastuzumab-SMCC were carried out in similar manners to that of (DOTA)m-PAMAM G3.0-sulfhydril. The positive fractions containing trastuzumab-SMCC were fractions numbered [14][15][16][17][18][19]. The result of a colorimetric assay of F(ab') 2 -trastuzumab-SMCC is shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

“…The formation of the ( 177 Lu-DOTA)m-PAMAM G3.0-F(ab') 2 -trastuzumab complex was performed by reacting a DOTA-PAMAM G3.0-F(ab') 2 -trastuzumab conjugate with 3+ , which was not bound to the DOTA-PAMAM G3.0-F(ab') 2 -trastuzumab [16]. The labeling percentage of the ( 177 Lu-DOTA)m-PAMAM G3.0-F(ab') 2 -trastuzumab before and after passing through the column was determined using thin layer chromatography (of ITLC-SG and saline solution as stasionary and mobile phases, respectively).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Radiolabeled Antibody Fragment for Preparation of (177Lu-DOTA)m-PAMAM G3.0-F(ab’)2 trastuzumab as a Radiopharmaceutical for Cancer Therapy

et al. 2017

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 90%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Radiolabeled Antibody Fragment for Preparation of (177Lu-DOTA)m-PAMAM G3.0-F(ab’)2 trastuzumab as a Radiopharmaceutical for Cancer Therapy

et al. 2017

View full text Add to dashboard Cite

“…The same procedure was repeated, incubating the complex in phosphate buffer samples (pH 7.4) at room temperature. Each of experiments was repeated twice and radiochemical purity of samples was calculated by g-counter (Rahmania, Mutalib, Ramli, & Levita, 2015).…”

Section: 8mentioning

confidence: 99%

Synthesis and stability test of radioimmunoconjugate 177Lu-DOTA-F(ab′)2-trastuzumab for theranostic agent of HER2 positive breast cancer

Hermanto

Haryuni

Ramli

et al. 2016

Journal of Radiation Research and Applied Sciences

Self Cite

View full text Add to dashboard Cite

The use of trastuzumab as intact IgG labeling radionuclide for HER2 positive breast cancer theranostic agent is not ideal because it is slowly eliminated from the blood and normal tissues resulting in low tumor/blood (T/B) and tumor/normal tissue (T/NT) ratios. To overcome this limitation, we developed the trastuzumab F(ab 0) 2 fragments and radiolabeling of the fragments by b and g-particle of Lutetium-177. F(ab) 2 fragments were produced by digestion of trastuzumab IgG (Herceptin) with pepsin for 18 h at 37 C. The F(ab 0) 2 fragment fractionated in PD-10 column, followed by the conjugation with 2-(4isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (p-SCN-Bn-DOTA) as a metal chelator and radiolabeling with 177 LuCl 3. Molecular weight of fragments was calculated by LCMS (Liquid Chromatography Mass Spectroscopy) and the radiochemical purity was evaluated by ITLC-SG (Instan Thin Layer Chromatography). Our study showed that the purity of F(ab 0) 2 fragment generated by PD-10 fractions was >98% and the molecular weight of F(ab 0) 2 was 98.35 kDa. The average numbers of pSCN-Bn-DOTA chelates per antibody fragment were 5.03 ± 1.5 and the optimum conjugation reactions was performed at molar ratio 20:1 (chelator to antibody). The stability test of the radioimmunoconjugate in the human serum albumin (HSA) at 37 C showed the radiochemical purity was 91.96 ± 0.26% after 96 h storage. This indicated that the radioimmunoconjugate is relatively stable when applied to the human body's physiological condition.

show abstract

“…The target is that the contrast compound would be able to be retained in intracellular and a clearer image. Hardiani et al have successfully performed the synthesis and stability test of Radiogadolinium (III) Gadolinium-DOTA-PAMAM (Poliamidoamine) Generation 3.0-Trastuzumab as SPECT contrast agent (Single Photon Emission Computed Tomography) -MRI contrast agent for breast cancer diagnostics [5][6][7]. Previous result successfully demonstrated a strong signal intensity increase on MRI examination with the Gd-DOTADendrimer-Trastuzumab contrast compound against the SKOV3 cell line.…”

Section: Introductionmentioning

confidence: 99%

Dendrimer-Trastuzumab Contrast Agent Improves Imaging of Magnetic Resonance Imaging (MRI) On Her2 Positive Breast Cancer Cell Line HCC-1954 in Apple Scaffold

Soekersi¹,

Mh²,

Huda³

et al. 2017

OMICS J Radiol

View full text Add to dashboard Cite

Synthesis and stability test of radiogadolinium(III)-DOTA-PAMAM G3.0-trastuzumab as SPECT-MRI molecular imaging agent for diagnosis of HER-2 positive breast cancer

Cited by 11 publications

References 17 publications

Radiolabeled Antibody Fragment for Preparation of (<sup>177</sup>Lu-DOTA)<sub>m</sub>-PAMAM G3.0-F(ab’)<sub>2</sub> trastuzumab as a Radiopharmaceutical for Cancer Therapy

Radiolabeled Antibody Fragment for Preparation of (<sup>177</sup>Lu-DOTA)<sub>m</sub>-PAMAM G3.0-F(ab’)<sub>2</sub> trastuzumab as a Radiopharmaceutical for Cancer Therapy

Synthesis and stability test of radioimmunoconjugate 177Lu-DOTA-F(ab′)2-trastuzumab for theranostic agent of HER2 positive breast cancer

Dendrimer-Trastuzumab Contrast Agent Improves Imaging of Magnetic Resonance Imaging (MRI) On Her2 Positive Breast Cancer Cell Line HCC-1954 in Apple Scaffold

Contact Info

Product

Resources

About